|
May 12
|
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
|
|
May 11
|
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
|
|
May 10
|
Novo Nordisk enters deal to develop obesity therapy
|
|
May 9
|
Making Money Off the Weight-Loss Revolution Has Even Wall Street Befuddled
|
|
May 9
|
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
|
|
May 9
|
Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster
|
|
May 9
|
Novo taps another Flagship startup in search for next obesity drugs
|
|
May 8
|
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
|
|
May 7
|
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
|
|
May 7
|
13 Best Stocks That Will Always Grow
|
|
May 6
|
Trading in Novo Nordisk shares by board members, executives and associated persons
|
|
May 6
|
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
|
|
May 6
|
Investors Pile Into Amgen in Search of Next Obesity Drug Payout
|
|
May 6
|
Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor
|
|
May 4
|
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
|
|
May 4
|
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
|
|
May 3
|
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
|
|
May 3
|
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Analyst unveils Amgen stock price target after weight-loss drug data
|
|
May 3
|
Weight-loss drug competition heats up. Is Wegovy in trouble?
|